undamentalytics Newsletter
Sign in

Nutex Health Inc. (NUTX) stock

Add to watchlist

Add holding +

NASDAQ: NUTX Nasdaq Health Care Facilities Next results ~November 5, 2026

Nutex Health Inc. is a US-listed company in the health care facilities industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$310

Valuation models combined (2)

Base case. Range ~$140–$390. Weighted average of 2 models (forward price-to-earnings vs peers, forward price-to-sales vs peers).

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Nutex Health Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders5 buying, 1 selling5 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds99 adding, 47 cuttingOf 25 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 89% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 18.6% over 90 days.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 90% and a beta of 1.7 against the S&P 500.
  • Heavily shorted. 28.6% of the shares available to trade are sold short (7.8 days of average volume to cover).
  • Earnings expected to fall. The consensus expects earnings per share to fall 0% next year.

Latest results

Earnings per share
$9.38 against an average estimate of $4.95: beat by 89.3%
Share reaction
+3.1% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026

Nutex Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.3%
  • 1 week-11.2%
  • 1 month-14.3%
  • This year+12.7%
  • 1 year+50.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results
  5. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Nutex Health Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Nutex Health Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.09 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: no revenue, margin or share count to start from
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$390 ~$410–$540 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$140 ~$120–$210 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$310 ~$140–$390 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Nutex Health Inc. with Health Care Facilities in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $215m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $27.37 +161% $870m −1%
Next $27.32 −0% $960m +10%

Next year's EPS estimate has moved +18.6% in 90 days, across 6 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +27.2% on 90 days ago. In the last 30 days, 5 analysts raised Nutex Health Inc.'s forecast and 0 cut it.

Consensus EPS forecast Nutex Health Inc., last 90 days
$20.00 $22.00 $24.00 $26.00 $28.00 $30.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $21.52 Current fiscal year, 60 days ago: $28.30 Current fiscal year, 30 days ago: $27.79 Current fiscal year, 7 days ago: $27.79 Current fiscal year, Now: $27.37 $27.37 Next fiscal year, 90 days ago: $23.03 Next fiscal year, 60 days ago: $28.83 Next fiscal year, 30 days ago: $27.87 Next fiscal year, 7 days ago: $27.87 Next fiscal year, Now: $27.32 $27.32

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $21.52$23.03
60 days ago $28.30$28.83
30 days ago $27.79$27.87
7 days ago $27.79$27.87
Now $27.37$27.32

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $4.95 $9.38 +89.3%
Mar 2026 $5.56 $5.74 +3.2%
Dec 2025 $5.56 $1.62 −70.8%
Sept 2025 $1.95 $7.76 +297.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026156
  2. Sep 2026145
  3. Aug 2026145

Counts of recommendations published by analysts covering Nutex Health Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
28.6%
of tradable shares
Days to cover
7.83
at average volume
Short interest, 1 month
+0%
to October 15, 2026
Held by institutions
44%
of shares
Held by insiders
29.2%
of shares
Employees
1,037
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
NUTX−91%+17%+420%+13%
Industry peers (median)+14%+12%+30%+4%
S&P 500+26%+25%+18%+11%
Months that ended higher
NUTX17%50%58%46%
S&P 50067%75%75%46%
Largest fall from a high during the year
NUTX−91%−88%−54%−53%
S&P 500−10%−8%−19%−9%

Worst fall since April 4, 2022: 100% from April 4, 2022 to July 9, 2024. Getting back needed a 138149% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$87.01 – $225.00
From 52-week high
−17.5%
vs 50-day average
−8.7%
vs 200-day average
+23.3%
Volatility (1 year)
90%
Beta vs S&P 500
1.74

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±19.9%
After a week
9 up, 3 down
typical move ±25.6%
After a month
10 up, 2 down
typical move ±43.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +3.1% +0.5% +18.8% +22.9%
April 30, 2026 +24.6% +1.3% +20.1% +14.3%
March 5, 2026 −16.7% −1.9% −19.8% −7.2%
November 19, 2025 +43.5% −1.1% +13.7% +73.3%
November 18, 2025 +7.9% −0.5% +14.7% +60.5%
October 20, 2025 +20.7% +1.0% +36.5% +4.6%
August 21, 2025 −0.4% +1.1% −4.7% +7.5%
August 14, 2025 −11.7% −0.2% −8.6% −9.1%
May 13, 2025 +27.4% +0.8% +42.2% +0.2%
March 31, 2025 +38.2% +1.0% +45.9% +112.8%
November 7, 2024 +16.2% +1.2% +15.3% +40.6%
August 8, 2024 +29.0% +2.8% +66.8% +166.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Hospital Division $844M 96.4% ▲ 88.0%
Population Health Management Division $31.1M 3.6% ▲ 0.7%
Products and services
Line of business Revenue Share YoY
Hospital Division $844M 96.4% ▲ 88.0%
Population Health Management Division $31.1M 3.6% ▲ 0.7%

From Nutex Health Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$502M
Institutions reporting
154
Shares held vs prior quarter
▲ 4.7%
Positions opened / closed
36 / 12

Top buyers and sellers, Q2 2026: 99 institutions bought and 47 sold ; the biggest buyer was D. E. Shaw & Co., Inc (+97K shares) and the biggest seller Topline Capital Management, LLC (−136K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Pertento Partners LLP $77.1M 451K 15.4% ▲ 20.7%
Blackrock, Inc. $69.6M 407K 13.9% ▲ 7.4%
American Century Companies Inc $40.6M 237K 8.1% ▲ 16.7%
Vanguard Capital Management LLC $36.9M 216K 7.4% ▼ 1.5%
Geode Capital Management, LLC $22.6M 132K 4.5% ▲ 8.1%
State Street Corp $22.4M 131K 4.5% ▲ 6.2%
D. E. Shaw & Co., Inc. $16.7M 97K 3.3% New
UBS Group AG $13.3M 78K 2.7% ▲ 12.0%
Winmill & Co. Inc $11.2M 65K 2.2% 0.0%
Focus Partners Wealth $10.4M 61K 2.1% New
Millennium Management LLC $8.9M 52K 1.8% ▼ 41.8%
Goldman Sachs Group Inc $8.8M 51K 1.7% ▲ 51.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nutex Health Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $148,237 5 trades by 5 insiders, last 12 months Insider sales History → $43,493 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $104,744 net buying
Insider Date Trade Shares Price Value
Saunders Scott J Director September 18, 2026 Sell 203 $214.25 $43,493
Jaumot Frank E Director March 20, 2026 Buy 150 $93.56 $14,034
Hosseinion Warren President March 19, 2026 Buy 252 $94.07 $23,706
Spears Kelvin Director March 17, 2026 Buy 10 $94.46 $945
Montgomery Pamela W. Chief Legal Officer-Healthcare March 13, 2026 Buy 79 $88.87 $7,021
Bates Jon Christian Chief Financial Officer November 25, 2025 Buy 750 $136.71 $102,532

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • April 30, 2026
  • March 5, 2026
  • November 19, 2025
  • November 18, 2025
  • October 20, 2025

Recent SEC filings

Data status

When each part of this page on Nutex Health Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Nutex Health Inc. in brief

What does Nutex Health Inc. do?
Nutex Health Inc. is a US-listed company in the health care facilities industry. Its financial year ends in December.
What is Nutex Health Inc.'s stock ticker?
Nutex Health Inc. trades under the ticker NUTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Nutex Health Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Pertento Partners LLP, Blackrock, Inc. and American Century Companies Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Nutex Health Inc. stock?
Over the last 12 months, Nutex Health Inc.'s directors and officers reported 5 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Nutex Health Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nutex Health Inc. announces its own schedule.